Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer
April 04, 2023 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights
March 22, 2023 08:30 ET
|
Inozyme Pharma Inc.
- Founding CEO, Axel Bolte, MSc, MBA, to retire; Douglas A. Treco, Ph.D., to succeed as CEO - - Matthew Winton, Ph.D., appointed COO - - Upcoming clinical and regulatory milestones remain on track...
Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference
March 01, 2023 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701
February 16, 2023 07:30 ET
|
Inozyme Pharma Inc.
- Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial - - Rapid and...
Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023
February 06, 2023 07:30 ET
|
Inozyme Pharma Inc.
- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE) – BOSTON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq:...
Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress
January 09, 2023 08:30 ET
|
Inozyme Pharma Inc.
- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency at virtual event on Thursday, Feb. 16, 2023 – - Significant clinical and scientific...
Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency
December 05, 2022 08:30 ET
|
Inozyme Pharma Inc.
- Article in Orphanet Journal of Rare Diseases estimates genetic prevalence of ENPP1 Deficiency at 1 in 64,000 pregnancies, more than tripling prior estimate - - Company estimates addressable patient...
Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
December 01, 2022 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 10, 2022 08:30 ET
|
Inozyme Pharma Inc.
- Topline data from Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency on track for the fourth quarter of 2022 – - Topline data from Phase 1/2 clinical trial of INZ-701 in ABCC6...
Inozyme Pharma to Participate in Upcoming Investor Conferences
November 07, 2022 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...